Pazopanib for the second line treatment of metastatic renal cell carcinoma (discontinued)
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 November 2008
Topic area
  • Cancer
  • Urogenital

Cancer reform strategy Batch 1

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: Aberdeen HTA Group
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
14 April 2010 As you are aware, the Department of Health has asked us to carry out a single technology appraisal of pazopanib for the second line treatment of metastatic renal cell carcinoma, following the publication of the Cancer Reform Strategy.This appraisal began, in January 2010, with a consultation on the draft scope and provisional matrix.

Ministers have considered developments since this product was originally referred to NICE, including information received from the manufacturer in relation to this indication and the number of patients who may be eligible to receive pazopanib for the second-line treatment of mRCC in the future. As a result Ministers have now agreed that this topic should be removed from the NICE work programme.

If you have any questions, please contact the project manager for this appraisal, Cathryn Hall,on telephone number 020 7045 2240 or at email address

For further information on our processes and methods, please see our CHTE processes and methods manual